Health Trials

Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

ConditionOsteoporosis, Postmenopausal
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age50-85
Sponsor424 General Military Hospital

About this trial

A 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab

Eligibility criteria

Qualifiers

None

Disqualifiers

a bone disease other than postmenopausal osteoporosis

use of medications other than bisphosphonates or SERMS affecting bone metabolism during the last 12 months before entering the study

creatinine clearance <60 mL/min/1.73 m2

liver failure

Trial design

Treatments tested in this trial

  • Zoledronate or Alendronate

Treatment groups

125 Participants
are divided into 3 treatment groups

Sponsors and collaborators

424 General Military Hospital

Lead sponsor

Source ClinicalTrials.gov